Home > The ATTC/NIATx Service Improvement Blog > AMERSA People & Passion, Episode 3: Barriers to Treatment for Opioid Use Disorder: Why Aren’t Pharmacists Stocking Buprenorphine?
Jeffrey P. Bratberg, PharmD, Clinical Professor at the University of Rhode Island, studies community pharmacists' roles play regarding opioid safety, opioid overdose, harm reduction and opioid use disorders. He is a consultant or co-investigator on two federal grants, a randomized controlled trial of pharmacists’ use of a CPA to manage medications for opioid use disorder and a multi-state, randomized control trial testing the effectiveness of a pharmacist and pharmacy focused intervention to improve naloxone provision, nonprescription syringe access and buprenorphine dispensing in community pharmacies.
Lucas G. Hill, PharmD, BCPS, BCACP serves as PhARM Director, The University of Texas at Austin. Dr. Hill graduated from the UMKC School of Pharmacy and completed a combined residency/fellowship in the UPMC Department of Family Medicine. He is now a clinical assistant professor at The University of Texas at Austin College of Pharmacy where he founded the PhARM Program and led implementation of Operation Naloxone. Dr. Hill is the principal investigator for a five-year, $25 million TTOR grant which seeks to address the opioid crisis in Texas by educating health professionals and the public while conducting pragmatic research.
The opinions expressed herein are the views of the authors and do not reflect the official position of the Department of Health and Human Services (DHHS), SAMHSA, CSAT or the ATTC Network. No official support or endorsement of DHHS, SAMHSA, or CSAT for the opinions of authors presented in this e-publication is intended or should be inferred.